Transforming growth factor (TGF)-b signaling is a potent modulator of the invasive and metastatic behavior of breast cancer cells. Indeed, breast tumor responsiveness to TGF-b is important for the development of osteolytic bone metastases. However, the specific TGF-b isoforms that promote breast cancer outgrowth in bone is unknown. We demonstrate that expression of a TGF-b ligand trap, which neutralizes TGF-b1 and TGF-b3, in MDA-MB-231 breast cancer cells diminished their outgrowth in bone and reduced the severity of osteolytic lesion formation when compared with controls. We further show that a reduction or loss of TGF-b1 expression within the bone microenvironment of TGF-b1 þ /À and TGF-b1À/À mice significantly reduced the incidence of breast tumor outgrowth compared with wild-type animals. Interestingly, those tumors capable of growing within the tibiae of TGF-b1-deficient mice had upregulated expression of all three TGF-b isoforms. Finally, breast cancer cells expressing the TGF-b ligand trap showed a pronounced reduction in their ability to form osteolytic lesions when injected into the tibiae of TGF-b1 þ /À mice. Thus, our studies show that both host-and tumor-derived TGF-b expression plays a critical role during the establishment and outgrowth of breast cancer cells in bone.
Introduction
The bone represents the most common site of metastasis in breast cancer patients (Mundy, 2002; Coleman, 2006; Hess et al., 2006) . These skeletal metastases are typically characterized by excessive bone resorption (Kozlow and Guise, 2005) . Breast tumor cells secrete factors that promote the differentiation and activity of multinucleated osteoclasts, which are the resident bone cells responsible for bone resorption (Yoneda and Hiraga, 2005; Rose and Siegel, 2006) . In addition, the bone matrix is a reservoir of latent growth factors that can be released and activated during osteoclast-mediated bone resorption. These factors then function in a paracrine manner to promote breast cancer survival and growth within bone (Mastro et al., 2003; Kozlow and Guise, 2005) .
All three transforming growth factor-b isoforms (TGF-b1, TGF-b2 and TGF-b3) are present in bone; however, TGF-b1 is the most abundant (Hering et al., 2001a, b) . TGF-b isoforms bind to the TGF-b type II receptor (TbRII), which in turn recruits and activates the TGF-b type I receptor (TbRI) (Wrana et al., 1994; Groppe et al., 2008) . TGF-b1 and TGF-b3 directly bind to the extracellular domain (ECD) of TbRII, whereas efficient binding of TGF-b2 to TbRII is facilitated by betaglycan (TbRIII) (Wang et al., 1991; Lopez-Casillas et al., 1993) . The activated TGF-b receptor complex then initiates signaling through both Smad-dependent and -independent pathways (Moustakas and Heldin, 2005; Schmierer and Hill, 2007) .
Mouse models of experimental breast cancer metastasis to bone show that TGF-b signaling in breast tumor cells is critical for this process. Expression of a dominant negative TbRII significantly reduces the ability of MDA-MB-231 breast cancer cells to form osteolytic bone metastases, which can be rescued by expression of constitutively active TbRI (Yin et al., 1999) . In vivo selection approaches to isolate highly aggressive bone metastatic MDA-MB-231 breast cancer cells have identified TGF-b targets, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11) and connective tissue growth factor, which play important roles in breast cancer metastasis to bone (Yoneda et al., 2001; Kang et al., 2003) . Activation of both Smad-dependent and -independent pathways within breast cancer cells is important for the formation of osteolytic metastases (Kakonen et al., 2002) . Stable knockdown of Smad4 expression in these cells further reinforces the importance of Smad-mediated TGF-b signaling for promoting breast cancer metastasis to bone Deckers et al., 2006) . Furthermore, kinase inhibitors targeting TbRI reduce the incidence of bone metastases following left cardiac ventricle injection of MDA-MB-435 and MDA-MB-231 breast cancer cells (Bandyopadhyay et al., 2006; Ehata et al., 2007) . These animal-based studies support a role for TGF-b signaling within breast tumor cells that enable aggressive metastasis to bone. Finally, it was recently reported that greater than 50% of breast and prostate cancer patients with skeletal metastases show elevated serum levels of TGF-b1, which correlates with increased expression of markers indicative of enhanced TGF-b signaling (Baselga et al., 2008) .
Although these studies show an important role for TGF-b signaling in breast cancer metastasis to bone, they do not identify the specific TGF-b isoforms that are most important for this process. Notably, they do not determine whether the primary source of TGF-b required for the development of osteolytic metastases originates from the bone matrix, resident bone cells or the tumor cells themselves. To address these issues, we have used a selective TGF-b isoform-neutralizing ligand trap and TGF-b1-deficient mice to examine the relative importance of tumor cell-or host-derived TGF-b in the establishment and outgrowth of osteolytic lesions in bone. Our results show that the removal of TGF-b1 and TGF-b3 isoforms significantly impairs the progression of breast cancer lesions in bone. Moreover, we conclusively show that the bone microenvironment provides a significant source of TGF-b1 and that its removal imposes a selective pressure on breast cancer cells to overexpress TGF-b isoforms, which promote the formation of osteolytic bone lesions.
Results

TGF-b-neutralizing ligand trap impairs signaling induced by TGF-b1 and TGF-b3
We first determined the expression pattern of each TGFb isoform in parental MDA-MB-231 breast cancer cells that had been injected into the tibiae of athymic mice. MDA-MB-231 cells readily form osteolytic lesions (Figure 1a ) that fill the marrow space (Figure 1b) . We readily detected serine phosphorylated Smad2 throughout the tumor, suggesting that the TGF-b signaling pathway was active in MDA-MB-231 cancer cells (Figure 1c ). Immunohistocytochemical analysis further showed that MDA-MB-231 breast cancer cells predominately expressed TGF-b1, with more moderate levels of TGF-b2 and very little TGF-b3 detected within osteolytic lesions (Figures 1d-f) .
To assess the importance of the TGF-b isoforms for breast cancer cell outgrowth in bone, we first used a soluble ligand trap composed of the ECD of TbRII fused to the constant region of human IgG (Fc). This fusion protein has previously been used to study the impact of impaired TGF-b signaling on breast cancer progression and metastasis (Mourskaia et al., 2007) . Pooled populations harboring an empty vector control (VC) or the ligand trap (Fc:TbRII(ECD)) were established in parental MDA-MB-231 cells possessing an imaging reporter system that includes firefly luciferase (Minn et al., 2005) . To test the efficacy of the ligand trap, VC or Fc:TbRII(ECD)-expressing cells were allowed to condition media and subsequently challenged with increasing concentrations of TGF-b1, TGF-b2 or TGF-b3 (Supplementary Figure S1a-c) . VC cells showed a concentration-dependent increase in phospho-Smad2 levels in response to stimulation by all three TGF-b isoforms (Supplementary Figure S1a- Figure  S1a-c) . However, the ligand trap was incapable of neutralizing TGF-b2-induced signaling (Supplementary Figure S1b) . Immunoblot analysis further confirmed that the fusion protein was expressed to similar levels by trap-producing MDA-MB-231 cells, but was absent in VC cells .
To confirm that the Fc:TbRII(ECD) fusion protein functioned as a soluble ligand trap, we asked whether conditioned media (CM) from VC and Fc:TbRII(ECD)-expressing MDA-MB-231 cells could block TGF-b isoform signaling in a TGF-b responsive cell line. To perform this experiment, we used NMuMG cells, an immortalized normal mouse mammary cell line, which exhibits numerous TGF-b-induced responses (Northey et al., 2008) . NMuMG cells stimulated with 2 ng/ml of TGF-b1, TGF-b2 or TGF-b3, in the absence or presence of CM (1:10 dilution) from MDA-MB-231 VC cells, responded with robust Smad2 phosphorylation (Supplementary Figure S1d-f) . However, CM (1:10 dilution) from Fc:TbRII(ECD)-expressing MDA-MB-231 cells effectively blocked Smad2 activation by TGFb1 or TGF-b3, but remained ineffective against TGF-b2 (Supplementary Figure S1d-f) . Immunoblot analyses of whole cell lysates and CM, using an antibody specific to the ECD of TbRII, confirmed expression of the ligand trap (Supplementary Figure S1g) . These results show that the Fc:TbRII(ECD) fusion protein effectively neutralizes both TGF-b1 and TGF-b3 isoforms but fails to sequester TGF-b2.
Expression of the TGF-b ligand trap impairs breast tumor growth in the mammary fat pad We first determined whether expression of the ligand trap altered the growth characteristics of MDA-MB-231 breast cancer cells, relative to VC cells. While VC and Fc:TbRII(ECD)-expressing MDA-MB-231 cells grew at the same rate in vitro (Supplementary Figure S2a) , a clear and significant reduction in the growth of Fc:TbRII(ECD)-expressing tumors was observed in the mammary fat pad (Supplementary Figure S2b) . Immunohistocytochemical analysis confirmed that the expression of the ligand trap was absent in VC-derived mammary tumors and maintained in Fc:TbRII(ECD)-expressing mammary tumors in situ (Supplementary Figure S3a) . To investigate potential mechanisms for reduced mammary tumor outgrowth in cells expressing the ligand trap, we analysed the proliferative, angiogenic and apoptotic indices of these tumors by Ki67, CD31 and TUNEL staining, respectively. We did not observe statistically significant differences in any of these parameters between Fc:TbRII(ECD) and VC-derived end-stage mammary tumors (Supplementary Figure  S3b-d) . However, this does not preclude the possibility that these parameters are adversely affected by the ligand trap at earlier stages of tumor outgrowth.
Neutralization of TGF-b1 and TGF-b3 isoforms within the bone microenvironment impairs the formation of osteolytic lesions We next determined the effects of ligand trap expression on the ability of breast cancer cells to grow in the bone, following direct tibial injection. The tibial injection model was specifically chosen to focus our investigations on the importance of TGF-b isoforms in mediating tumor cell interactions with the bone microenvironment, thereby avoiding possible TGF-b effects on tumor cell survival in circulation, endothelial adhesion and extravasation. Immunohistocytochemical staining with an antibody against the ECD of TbRII confirms that breast cancer lesions retain expression of the ligand trap in vivo (Supplementary Figure S4a) . Examination of breast tumor cell proliferation, survival and recruitment of vasculature within osteolytic bone lesions failed to show statistically significant differences between VC and Fc:TbRII(ECD)-expressing MDA-MB-231 cells . Although the mechanisms remain unclear, these results indicate that neutralization of TGF-b1 and TGF-b3 isoforms significantly impairs the outgrowth of breast cancer cells in bone.
Transforming growth factor-b is known to induce the expression of factors important for osteoclast differentiation and function, such as PTHrP and IL-11 (Yin et al., 1999; Kang et al., 2003 Kang et al., , 2005 Deckers et al., 2006) . Thus, we investigated whether expression of the neutralizing ligand trap could blunt TGF-b-induced expression of these two factors. Vector control (VC) or Fc:TbRII(ECD)-expressing MDA-MB-231 breast cancer cells were allowed to condition serum free media for 48 h and subsequently incubated in the absence or presence of TGF-b1 for a further 3 h. Quantitative Loss or reduction of TGF-b1 levels in host-derived tissue prevents the efficient establishment of breast cancer cells in bone To specifically interrogate the importance of bonederived TGF-b1 on the ability of breast cancer cells to form osteolytic lesions, we used TGF-b1-deficient mice that were bred onto a RAG2-deficient background (Engle et al., 1999) , which rescues the early lethality observed in TGF-b1-null mice due to widespread inflammatory disease (Shull et al., 1992; Kulkarni et al., 1993) . To ensure that the RAG2À/À mice permitted xenografting of human breast cancer cells, we injected an MDA-MB-231 variant that aggressively metastasizes to bone (1833-TR cells) into mammary fat pads of RAG2À/À mice (Kang et al., 2003; Minn et al., 2005) . Primary mammary tumors established and grew in 100% of TGF-b1 þ / þ ; RAG2À/À, . VC and Fc:TbRII(ECD)-expressing MDA-MB-231 cells were allowed to condition media for 48 h before a 3 h incubation in the absence (À) or presence ( þ ) of 5 ng/ml TGF-b1. Fc:TbRII(ECD)-expressing MDA-MB-231 cultures were changed to fresh media to remove any accumulated ligand trap and subjected to a 3 h incubation in the absence or presence of TGF-b1. The expression levels of each target gene were first normalized to b-actin and presented at a fold change relative to VC (ÀTGF-b1) ( ± s.d.) . The data represents the average of two independent experiments, each performed in triplicate. TGF-b1-induced fold changes in PTHrP and IL-11 expression were found to be statistically different in the absence of the ligand trap compared with conditions when the trap is present (*Po0.0001; **P ¼ 0.0008).
TGF-b1 þ /À; RAG2À/À and TGF-b1À/À; RAG2À/À animals ( Figure 3a) . Tumor outgrowth was found to be similar in the TGF-b1 þ / þ ; RAG2À/À and TGF-b1 þ /À; RAG2À/À cohorts. However, there was a significant reduction in the rate of mammary tumor growth in TGF-b1À/À; RAG2À/À mice (Figure 3a) .
To determine the effect of reduced host-derived TGFb1 expression on the ability of breast cancer cells to grow in bone, we injected 1833-TR cells into the tibiae of TGF-b1 þ / þ ; RAG2À/À, TGF-b1 þ /À; RAG2À/À and TGF-b1À/À; RAG2À/À mice. X-rays were taken at 8 weeks post-injection and blinded before being scored for the presence of osteolytic lesions. Approximately 72% of the tibial injections in TGF-b1 þ / þ ; RAG2À/À gave rise to osteolytic lesions compared with only 44% in TGF-b1 þ /À; RAG2À/À mice and 33% in TGF-b1À/À; RAG2À/À animals ( Figure 3b ). The dramatic effect observed in TGF-b1 þ /À; RAG2À/À mice most likely reflects the fact that TGF-b1 protein levels are reduced up to 60-90% of the levels observed in wild-type mice (Tang et al., 1998) . Interestingly, bioluminescence imaging showed that MDA-MB-231 breast cancer cells capable of establishing themselves in TGF-b1 þ / þ ; RAG2À/À, TGF-b1 þ /À; RAG2À/À and TGF-b1À/À; RAG2À/À mice grew out at similar rates ( Figure 4a ) and induced similar degrees of osteolytic bone destruction (Figure 4b) . Importantly, our results argue that reduced TGF-b1 levels in the host microenvironment are sufficient to negatively impact the ability of breast cancer cells to establish osteolytic lesions. Nevertheless, a subset of animals do develop lesions in a TGF-b1-deficient or -null background, suggesting that these lesions have developed compensatory mechanisms in response to attenuated host-derived TGF-b1 signaling.
Breast cancer cells capable of establishing lesions in TGF-b1-deficient mice compensate by upregulating the expression of TGF-b isoforms within the tumor Using an immunohistocytochemical approach, we examined the possibility that breast cancer cells emerging in a TGF-b1-deficient background could compensate for this loss by increasing tumor specific expression of the TGF-b isoforms. Osteolytic lesions formed in TGF-b1 þ / þ ; RAG2À/À mice showed readily detectable levels of TGF-b1, whereas TGF-b2 and TGF-b3 were very weakly expressed (Figure 5a, left panels) . Interestingly, tumor cell-specific expression of both TGF-b1 and TGF-b2 was significantly increased in a TGF-b1 þ /À; RAG2À/À host microenvironment, whereas there was no detectable increase in TGF-b3 staining (Figure 5a , middle panels). A further upregulation of TGF-b1 and TGF-b2 expression was evident, with a more modest but significant increase in TGF-b3 staining, in TGF-b1À/À; RAG2À/À mice (Figure 5a , right panels). This pattern of TGF-b isoform expression correlated with similar levels of Smad2 phosphorylation in osteolytic lesions derived from all three genetic backgrounds (Figure 5b ). These data show that a strong selective pressure is exerted upon tumor cells to retain TGF-b signaling during their outgrowth in the bone.
Simultaneous attenuation of TGF-b1 signaling within the breast tumor and the host microenvironment significantly impairs tumor outgrowth in bone To determine whether tumor cell intrinsic TGF-b1 signaling could compensate for diminished TGF-b1 expression in the bone microenvironment, we injected MDA-MB-231 breast cancer cells expressing the ligand trap into the tibiae of TGF-b1 þ / þ ; RAG2À/À or TGF-b1 þ /À; RAG2À/À mice. We chose TGFb1 þ /À; RAG2À/À mice given that the formation of 1833-TR cells were injected directly into the tibia of the TGF-b1 þ / þ , þ /À and À/À female mice, all on a RAG2À/À background. X-ray images of the indicated numbers of tibia were first blinded and scored for the presence of osteolytic bone lesions for each genotype (*P ¼ 0.027, **P ¼ 0.006).
TGF-b isoforms promote breast cancer outgrowth in bone AA Mourskaia et al osteolytic lesions was significantly reduced in TGFb1 þ /À and TGF-b1À/À animals; however, mammary tumor outgrowth was only impaired in the latter (Figure 3) . Injection of Fc:TbRII(ECD)-expressing MDA-MB-231 cells resulted in the development of osteolytic lesions in 34.6% (9/26) of TGF-b1 þ / þ ; RAG2À/À animals compared with 23.1% (6/26) in TGF-b1 þ /À; RAG2À/À mice. However, the growth of the resulting lesions was severely diminished when TGFb1 signaling was attenuated both within the tumor cell and in resident bone cells (Figure 6a ). Whereas most osteolytic lesions that developed in TGF-b þ / þ ; RAG2À/À mice were large, tumors arising in TGFb þ /À; RAG2À/À animals showed significantly lower luminescence signals (Figure 6b) . Indeed, the mean luminescence signal observed in tumors arising from TGF-b1 þ / þ ; RAG2À/À animals was 1.9 Â 10 8 p/s/ cm 2 /sr compared with 2.3 Â 10 7 p/s/cm2/sr in TGF- Figure S5) . Taken together, we show that neutralization of TGFb1 and/or TGF-b3 signaling by the soluble ligand trap severely diminishes the formation of osteolytic bone lesions in a TGF-b1-deficient background. Given that tumor cell intrinsic TGF-b1, but not TGF-b3, is strongly overexpressed in osteolytic lesions that formed in TGF-b1-deficient animals ( Figure 5 ), these observations argue that establishment of a TGF-b1 autocrine loop, provided either from the breast cancer cells themselves or the host tissues, is crucial for breast cancer outgrowth in the bone microenvironment.
Discussion
Previous studies suggest that TGF-b1 is the predominant isoform present in bone (Hering et al., 2001a, b; Janssens et al., 2005) . Here we show that MDA-MB-231 breast cancer cells express readily detectable levels of TGF-b1 and TGF-b2, but very low amounts of TGFb3, within osteolytic lesions in vivo. The Fc:TbRII(ECD) ligand trap preferentially binds and neutralizes TGF-b1
and TGF-b3, but not TGF-b2 (Supplementary Figure  S1 ) (Komesli et al., 1998) , due to amino-acid substitutions in TGF-b2 that reduce its affinity for the TbRII (De Crescenzo et al., 2006) . Expression of the ligand trap significantly inhibited the ability of breast cancer cells to grow effectively in the bone and suppressed TGF-b-induced expression of PTHrP and IL-11, two osteoclastic factors that are important for the formation of breast cancer bone metastases (Manolagas, 1995; Yin et al., 1999; Sotiriou et al., 2001; Kakonen et al., 2002; Kang et al., 2003 Kang et al., , 2005 Deckers et al., 2006; Liao and McCauley, 2006) . These results are consistent with the observation that a dominant negative TbRII or a TbRI inhibitor impaired the ability of breast cancer cells to metastasize to bone (Yin et al., 1999 that an increase in the local concentration of the ligand trap would be achieved as Fc:TbRII(ECD)-producing tumors progressively grow in the bone. These increasing amounts of the secreted ligand trap would neutralize TGF-b1 and TGF-b3 that are (1) produced by resident bone cells, (2) released from the matrix during the induction of an osteolytic response or (3) secreted by the mammary tumor cells themselves. Ultimately, this would dampen the expression of pro-osteoclastic factors, resulting in diminished tumor growth of TGF-b ligand trap-expressing cells.
The expression of Fc:TbRII(ECD) is not sufficient to abrogate tumor growth in the bone, but results in a significant delay in outgrowth of osteolytic lesions. This may reflect the fact that expression of the various TGFb isoforms, regardless of their source, is simply in excess of the neutralizing capacity of the ligand trap. The observation that expression of the ligand trap dramatically impairs tumor outgrowth in a TGF-b1-deficient background argues that TGF-b1 is the predominant isoform that drives the efficient establishment and growth of osteolytic lesions in bone.
To extend the results obtained with the ligand trap approach, we used TGF-b1-deficient mice that were bred onto a RAG2À/À background. We cannot rule out the possibility that delayed tumor outgrowth observed within the mammary gland and tibiae of TGF-b1À/À; RAG2À/À mice is a result of general failure to thrive observed in these animals relative to heterozygous and wild-type controls. Moreover, TGF-b1-null mice possess defects in bone quality, including reduced bone mineral content and bone elasticity in the tibiae compared with heterozygote and wild-type mice (Geiser et al., 1998) . On the other hand, TGF-b1 þ / þ ; RAG2À/À and TGF-b1 þ /À; RAG2À/À mice are phenotypically indistinguishable with respect to overall health, bone quality and their ability to support mammary tumor growth in the primary site. Importantly, there remains a significant reduction in the ability of breast cancer cells to establish or grow in TGF-b1 þ /À; RAG2À/À tibiae compared with wild-type controls. This dramatic effect in TGF-b1 þ /À; RAG2 À/À mice may reflect the fact that TGF-b1 protein levels have been found to be reduced up to 60-90% of the levels observed in wild-type mice without a concomitant upregulation of TGF-b2 or TGF-b3 (Tang et al., 1998) . Thus, our results show that the reduced levels of TGF-b1 can have a profound effect on the ability of breast cancer cells to establish or grow in bone.
Although the TGF-b ligand trap was able to diminish tumor outgrowth in the bone, all tibiae injected with Fc:TbRII(ECD)-expressing breast cancer cells developed osteolytic lesions. In contrast, TGF-b1 deficiency reduced the incidence of osteolytic lesion formation. This difference between the effects of a neutralizing ligand trap versus reduced TGF-b1 expression may reflect the fact that the bone microenvironment in TGF-b1 þ /À and À/À mice cannot support the early survival of breast cancer cells compared with wild-type mice. Such a result would not be expected when using a ligand trap, given that the bone microenvironment, and thus the putative 'niche' sites where breast cancer cells first establish, would be unaltered before the arrival of the ligand trap-expressing breast cancer cells. A careful examination of the number of breast cancer cells that seed the bone marrow and survive over the initial few days post-injection may shed light on these questions.
Once established, lesions in TGF-b1 þ /À and À/À mice grew out at the same rate as those in TGF-b1 þ / þ animals by virtue of their ability to upregulate tumor cell-specific TGF-b isoform expression and signaling. Interestingly, expression of the ligand trap in MDA-MB-231 breast cancer cells profoundly diminished their ability to grow in a TGF-b1-deficient background. In this respect, the TGF-b ligand trap functioned in a similar manner in breast cancer cells that established themselves as growing lesions within the bone, regardless of the experimental system employed. This argues that the predominant effect of the ligand trap is to neutralize TGF-b isoforms that are either released and activated from bone or secreted by cancer cells, which results in diminished growth of the breast cancer cells. However, tumor outgrowth of Fc:TbRII(ECD)-expressing MDA-MB-231 cells was not completely abrogated in the tibiae of TGF-b1 þ /À animals. This may indicate that the levels of the TGF-b isoforms upregulated in breast cancer cells were too high to be fully neutralized by the ligand trap. Alternatively, tumor-specific expression of TGF-b2, which cannot be neutralized by the ligand trap, may compensate in the formation of osteolytic lesions but is not sufficient to permit aggressive growth of breast cancer cells in bone. To address this possibility, a soluble ligand trap capable of neutralizing all three TGF-b isoforms will need to be tested in the context of reduced host-derived TGF-b1 levels. Thus, our data show that TGF-b signaling, predominantly initiated by TGF-b1, is not only required within the breast cancer cells themselves but also within the bone microenvironment to create favorable conditions that support breast tumor cell outgrowth.
Materials and methods
DNA constructs
The human TbRII ECD fused to the Fc portion of human IgG (Fc:TbRII(ECD)) (del Re et al., 2004) was PCR-amplified and subcloned into a lentiviral plasmid vector designated pCSII-CMV-mcs-ires-DsRed (proprietary vector).
Cell culture
Parental MDA-MB-231 breast cancer cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and transduced with a triple reporter system as described (Minn et al., 2005) . The MDA-MB-231-derived bone metastatic cell population (1833-TR) has been described previously (Kang et al., 2003; Minn et al., 2005) . The NMuMG normal murine mammary gland epithelial cell line was obtained from the American Type Culture Collection and cultured as previously described (Northey et al., 2008) .
Lentivirus harboring the empty VC or Fc:TbRII(ECD) plasmids was produced and amplified in the packaging cell line 293SF-PacLV clone 29-6, as described previously (Broussau et al., 2008) . MDA-MB-231 cells were subjected to two rounds of infection with either VC or Fc:TbRII(ECD) carrying lentivirus (M.O.I. 10 transduction units/cell), as previously described (Broussau et al., 2008) .
Bioluminescence and X-ray imaging Tumor outgrowth within the bone was monitored using an IVIS 100 (Caliper Life Sciences, Mountain View, CA, USA) bioluminescence imaging system. Briefly, mice were anaesthetized by isoflurane inhalation, injected intraperitoneally with D-luciferin potassium salt (75 mg/kg; Xenogen/Caliper Life Sciences, Mountain View, CA, USA) and imaged 10 min following substrate injection. Images were analysed with Living Image Software. Bioluminescent signals within the tibiae were normalized to the background luminescence taken over the same region of interest from uninjected animals. Mice were killed between weeks 4 and 8 post-tibial injection and digital X-rays were obtained with a Faxitron Specimen Radiography System. All X-rays were blinded and evaluated by two readers (AAM and PMS). The size of osteolytic lesions was expressed as percentage area occupied by osteolytic lesions over the total tibial area measured from blinded X-rays. Both osteolytic area and total area of tibiae were quantified using ImageJ software. Animal experiments were conducted under a McGill University approved Animal Use Protocol in accordance with the guidelines established by the Canadian Council on Animal Care.
Immunohistocytochemistry
Bone samples were fixed overnight in 4% paraformaldehyde and further decalcified with 10% EDTA disodium salt. Immunohistocytochemistry was performed with the following antibodies: TGF-b1 (1:100 dilution; Santa Cruz Biotechnology; Santa Cruz, CA, USA), TGF-b2 (1:200 dilution; Santa Cruz Biotechnology), TGF-b3 (1:150 dilution; Santa Cruz Biotechnology) and Phospho-Smad2 (Ser465/467) (1:150 dilution; Cell Signaling; Danvers, MA, USA). Appropriate biotin-SP-conjugated anti-IgG secondary antibodies were purchased from Jackson Laboratories; Bar Harbor, ME, USA. Slides were first scanned using a Scanscope XT digital slide scanner (Aperio, Vista, CA, USA) and further analysed using Imagescope software (Aperio) using either positive pixel count or immunohistochemistry nuclear algorithms.
Quantitative RT-PCR Total RNA was isolated using an RNeasy kit (Qiagen; Mississauga, ON, Canada) and 1 mg of RNA from each sample was reverse transcribed using the High capacity cDNA Reverse Transcription kit (Applied Biosystems; Foster City, CA, USA) in accordance with the manufacturer's instructions. The resulting cDNAs were used for real-time PCR using Power SYBR Green PCR Master Mix (Applied Biosystems). Reactions were carried out in a 7500 Real-time PCR System (Applied Biosystems) for 40 cycles (95 1C for 15 s, 60 1C for 30 s and 72 1C for 45 s) after the initial 10-min incubation at 95 1C. See Supplementary Information for primer sequences. A C t value for each reaction was calculated using Applied Biosystems Sequence Detections Software and the relative ratio of expression was determined using a previously described algorithm (Pfaffl, 2001 ).
Statistical analysis
Statistical significance values for primary tumor growth, bioluminescence, osteolytic lesion area, quantitative RT-PCR and TGF-b isoform staining data were obtained by performing a two-sample variance student's t-test. The Fisher's exact test was performed to analyse the probability of the occurrence of osteolytic lesions in TGF-b1 þ / þ ; RAG2À/À, TGF-b1 þ /À; RAG2À/À and TGF-b1À/À; RAG2À/À mice.
Abbreviations
CM, conditioned media; ECD, extracellular domain; IL-11, interleukin-11; PTHrP, parathyroid hormone-related protein; TbRI, TGF-b type I receptor; TbRII, TGF-b type II receptor; TGF-b, transforming growth factor b; VC, vector control.
